BioBulk™️: Positioning for Capacity Synergy

BioBulk™️: Positioning for Capacity Synergy
Synthetic Biology: Leading the Third Biotechnology Revolution
Synthetic biology, known as the "third biotechnology revolution," centers on designing and engineering biological systems to function as "cell factories" that produce substances needed by humanity. The foundation of this capability is DNA synthesis—a technology capable of creating DNA sequences from scratch. While traditional gene editing involves patching existing DNA frameworks, DNA synthesis represents design from the ground up, elevating the manipulation of living organisms to a new level.
DNA synthesis technologies are primarily divided into chemical and biological methods. Enzymatic synthesis, a next-generation biological method, uses bio-enzymes to synthesize DNA in aqueous reactions, offering higher accuracy and environmental benefits. For instance, ZH Gene's TIESyno-96™ DNA biosynthesizer can perform de novo synthesis without templates, with key metrics reaching international leading standards.
Applications of synthetic biology have already entered daily life. In the medical field, during the 2013 H7N9 avian flu outbreak, Chinese scientists sequenced the viral genome and uploaded it to the web; foreign teams used DNA printers to synthesize viral DNA within 12 hours—much faster than traditional egg-culture methods—allowing for early vaccine preparation. For Vitamin B12, traditional chemical methods involved too many steps for mass production; now, through heterologous expression of 28 genes in E. coli, the fermentation cycle is only 1/10 that of industrial strains, with yields reaching 307 µg/g of dry cell weight.
In the food sector, Ginkgo Bioworks collaborates with fragrance company Robertet to produce fragrance ingredients via yeast fermentation, which is more stable and eco-friendly. Precision fermentation also produces artificial proteins, reducing carbon emissions from livestock. In agriculture, nitrogen-fixing microbial technology allows crops to absorb nitrogen from the air, reducing fertilizer use; technology developed by Ginkgo and Bayer is currently under testing.
The global synthetic biology market is growing rapidly. McKinsey predicts its economic value will reach $100 billion by 2025 and impact $1.8–3.6 trillion annually between 2030 and 2040. China is advancing quickly in this field, backed by vast market demand and policy support (the "14th Five-Year Plan" for the bioeconomy lists synthetic biology as a priority). Companies are innovating: Cabio has built a biological computing platform using AI to discover "dark matter" within cells, aiding in the design of superior strains. Its microcapsule workshop has achieved unmanned operations, using big data and AI to control fermentation, breaking the "empiricism" bottleneck of traditional biomanufacturing. However, China faces shortcomings: reliance on imported underlying gene synthesis equipment and high-end reagents, and insufficient engineering scale-up capabilities—many promising lab strains fail during factory scale-up due to mismatched process parameters.
In the future, AI will serve as the "brain" of synthetic biology. DeepMind's AlphaFold can already predict 200 million protein structures—1,000 times more than the previous PDB database—aiding in the design of more efficient enzymes or entirely new proteins. Bio-foundries will scale up; automated platforms like Ginkgo's integrate DNA synthesis, editing, and testing, lowering costs as project volume increases. Green manufacturing is the trend, with biological chemical production reducing emissions by 30%–70% compared to chemical methods, aligning with "carbon neutrality" goals.
Synthetic biology is not science fiction, but a revolution in progress. From DNA synthesis to "cell factories," from vaccines to food, it is transforming the way materials are produced. Despite challenges like DNA synthesis length limitations and engineering scale-up, the future of "manufacturing all things via biology" is gradually approaching.
U3X BIOBULK is dedicated to global capacity development, resource asset allocation, and technology acquisition for biologically synthesized commodities.